focus -WSS

focus

author：entertainment 2025-09-29 21:27:35 - browse：8132

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： A preacher's new calling: Diversifying neuroscience research

WSS

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

How I helped Pfizer think through the ethics of Viagra

A controversial new treatment promises to make little people taller

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Medicare Advantage overpayments discussion gets experts fired up

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Wikipedia

focus

hotspot

Drug repurposing or repositioning? The language matters

CDC recommends RSV monoclonal antibody for infants

Apple is now the first public company to be valued at $3 trillion

Fauci's latest grilling in Congress: 9 hours, behind closed doors

The cancer drug shortage isn’t new — and neither are the solutions

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

The high cost of giving birth even with insurance

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

New air purifier tech could be key to improving indoor air quality

Gene therapy denied for Afghan refugee whose father aided U.S.

focus

How I helped Pfizer think through the ethics of Viagra

Profiling embryos to choose those with higher IQs is almost a reality

Does Paxlovid work in people vaccinated against Covid

FDA early review: GLP

A controversial new treatment promises to make little people taller

STAT Virtual Event: JPM Recap, Live!

focus

hotspot

knowledge

knowledge